Melanotan and Priapism: What a BMJ Case Report Explains
Melanocortin analogues, commonly referred to as melanotan, are illegally used by individuals seeking an artificial tan. Beyond skin pigmentation, these substances exert systemic biological effects that can lead to severe health events. Clinicians and researchers examine these outcomes through peer-reviewed medical publications to better understand unexpected physiological harm.
What Did the 2019 BMJ Case Report Document?
In 2019, the medical journal BMJ case reports published a paper titled Melanotan-induced priapism: a hard-earned tan. indexed under PMID 30796078. The study presented a patient who arrived at an accident and emergency department before being assessed in a specialized tertiary urology centre. The emergency presentation occurred following an abdominal subcutaneous injection of melanotan.
While melanocortin analogues have been studied or suggested as possible therapeutic agents in the treatment of erectile dysfunction, their unlicensed and unsupervised use poses acute physical hazards. The authors highlighted that acute priapism was an unreported side effect of melanocortin analogue use prior to this event, marking it as a critical safety concern for health professionals evaluating patients with unexplained urological emergencies.
How Was the Condition Diagnosed in This Medical Emergency?
Upon evaluation at the tertiary urology centre, physicians diagnosed the patient with acute priapism, specifically classifying it as "low-flow" priapism. Low-flow priapism is a medical emergency characterized by persistent, painful engorgement where blood becomes trapped inside the cavernosal bodies of the penis.
Without prompt intervention, low-flow priapism can trigger progressive tissue ischemia and permanent injury. The clinical team recognized the severity of the event, linking the onset directly to the patient's recent subcutaneous administration of melanotan into the abdomen. Readers exploring unexpected reactions can review wider documentation in Melanotan Side Effects Reported in Medical Journals.
How Did the Urology Centre Manage the Patient's Care?
Managing acute low-flow priapism requires urgent procedural intervention to relieve pressure, clear deoxygenated blood, and restore vascular equilibrium. The hospital team initiated a multi-step bedside urological protocol rather than moving immediately to open surgery:
- Cavernosal aspiration to decompress the rigid erectile tissues
- Cavernosal irrigation to wash out stagnant blood
- Subsequent intracavernosal injection of phenylephrine to induce vasoconstriction and detumescence
Through these progressive emergency measures, the clinical team managed the complication without surgical intervention, allowing the individual to avoid requiring surgical shunting. Surgical shunts are typically reserved for refractory episodes that fail medication and aspiration, carrying additional surgical risks.
What Were the Patient's Outcomes at the 4-Week Follow-Up?
Although the emergency team resolved the immediate physical engorgement without surgical shunting, the patient experienced lingering vascular consequences. At a 4-week follow-up evaluation, the patient had not yet recovered erectile function.
The study authors emphasized that future therapeutic application of melanocortin agents will need to take this potential life altering complication into serious consideration. The persistence of erectile dysfunction at the four-week mark demonstrates that severe reactions to unregulated melanocortin analogues can cause lasting impairment long after the acute emergency has subsided.
What Are the Limits and Design of This Study?
When reading medical research, it is essential to contextualize the study design and avoid broad generalizations. The evidence presented in this publication is classified under case reports and review literature. It details the clinical course of exactly one patient under hospital care.
Because this is an isolated case report, it has clear structural limitations:
- It documents a single clinical observation rather than a controlled clinical trial
- It cannot determine population-wide incidence rates or calculate statistical risk percentages for all users
- It reflects an unregulated, illegally obtained substance where exact purity, compounding methods, or contaminants remain unverified
Even with these limitations, single case reports alert the medical community to life-altering outcomes. Anyone considering tanning peptides should understand that these substances are unapproved, unregulated, and capable of triggering severe medical emergencies. Questions regarding sexual health, pigmentation, or related medications like Bremelanotide (Vyleesi) should always be discussed with a qualified doctor.
For additional details regarding this clinical presentation, consult the PubMed record for PMID 30796078.
Sources
Melanotan-induced priapism: a hard-earned tan. - PubMed (PMID 30796078)
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.